Merus N.V. - Common Shares (MRUS)
93.73
+24.84 (36.06%)
NASDAQ · Last Trade: Sep 29th, 3:11 PM EDT
U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500 also rose, gaining, 0.13% to 6,652.27.
Via Benzinga · September 29, 2025
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44. The company's market cap stands at $156.6 million.
Via Benzinga · September 29, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via Chartmill · September 29, 2025
Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Racestocktwits.com
Via Stocktwits · September 28, 2025
U.S. stocks were mixed, with the Nasdaq Composite gaining more than 100 points on Monday. Shares of Tilray Brands, Inc. (NASDAQ: TLRY) rose sharply during Monday's session.
Via Benzinga · September 29, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · September 29, 2025
Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V.
Via Benzinga · September 29, 2025
In the preceding three months, 4 analysts have released ratings for Merus (NASDAQ: MRUS), presenting a wide array of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Via Benzinga · September 29, 2025
The takeover candidate is working on a bispecific antibody, capable of simultaneously blocking two drivers of cancer.
Via Investor's Business Daily · September 29, 2025
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · September 29, 2025
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.
Via Benzinga · September 29, 2025
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.
Via Benzinga · September 29, 2025
MERUS NV (NASDAQ:MRUS) shows strong technicals with a 7/10 rating and a high-quality 9/10 setup, suggesting a potential breakout above $56.23. Support at $52.32-53.52 provides a clear risk level.
Via Chartmill · July 14, 2025

Via Benzinga · June 4, 2025

11 mid-cap stocks soared last week, including LZ Technology, Centrus Energy, e.l.f Beauty, Merus, Oklo, NuScale Power, Informatica, BRP, Box, Joby Aviation, and C3.ai.
Via Benzinga · June 1, 2025
Top mid-cap stocks gained up to 53.47% in the last week, including QBTS, RGC, AAP, MRUS, OKLO, SBSW, and BGM. Are they in your portfolio?
Via Benzinga · May 25, 2025
Merus N.V. (NASDAQ: MRUS) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab for head and neck cancer.
Via Benzinga · May 23, 2025
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · May 23, 2025
BofA’s new price target of $92 implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.
Via Stocktwits · May 23, 2025
Via Benzinga · May 23, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · May 23, 2025
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge.
Via Investor's Business Daily · May 23, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · May 23, 2025

Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for petosemtamab in combination with pembrolizumab.
Via Benzinga · February 18, 2025